Vertex Pharmaceuticals VRTX
- Market cap
- $137.8B
- PE
- 31.6×
- 9y median 28.6×
- Forward PE
- 28.0×
- 10y median 26.4×
- Price to sales
- 10.9×
- EV/EBIT
- 28.1×
- Revenue, 12 months
- $13B
- +10% on a year ago
- Net margin
- 35.0%
- Free cash flow yield
- n/m
- Q3 FY26 missing
Vertex Pharmaceuticals trades at 31.6× trailing earnings, pricier than 69% of the last ten years. Revenue was $13B over the last twelve months, up 10% on a year earlier with a 35% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.5B+9% | $2.7B+13% | $2.6B+6% | $2.8B+12% | $2.9B+16% | $2.8B+3% | $3B+12% | $3.1B+11% | $3.2B+10% | $3B+8% | $3.3B+13% | $3.4B+12% | |
| Cost of revenue | $368M+30% | $342.6M+28% | $371.9M+21% | $392.6M+23% | $423.4M+15% | $363M+6% | $407.5M+10% | $414.8M+6% | $466M+10% | $392.8M+8% | $489.2M+20% | $526.1M+27% |
| Gross profit | $2.1B+7% | $2.3B+11% | $2.3B+4% | $2.4B+10% | $2.5B+16% | $2.4B+3% | $2.6B+13% | $2.7B+12% | $2.7B+10% | $2.6B+8% | $2.8B+11% | n/a |
| R&D | $824.6M+19% | $789.1M+6% | $966.6M+23% | $875.9M+8% | $998.7M+21% | $979.7M+24% | $978.4M+1% | $977.7M+12% | $973.7M−3% | $961.6M−2% | $993.8M+2% | $1.3B+35% |
| SG&A | $369.1M+38% | $342.7M+42% | $372.2M+42% | $371.8M+41% | $377.6M+2% | $396.4M+16% | $424.6M+14% | $445.1M+20% | $487M+29% | $493.7M+25% | $582.2M+37% | $844.1M+90% |
| $988.5M−4% | $1.1B+46% | −$3.5B | $1.1B+8% | $1B+4% | $630.1M−45% | $1.2B | $1.2B+6% | $1.2B+18% | $1.1B+81% | $1.2B+8% | $712.9M−40% | |
| Interest expense | $10.6M−9% | $10.4M−9% | $9.9M−12% | $7.5M−31% | $2.8M−74% | $3M−71% | $3.7M−63% | $3.3M−56% | $3.3M+18% | n/a | n/a | n/a |
| Pre-tax income | $1.1B+7% | $1.3B+44% | −$3.4B | $1.2B+4% | $1.1B−1% | $730.4M−43% | $1.3B | $1.3B+6% | $1.3B+17% | $1.3B+72% | $1.4B+9% | $783.4M−40% |
| $178.8M−31% | $179.5M−6% | $202.4M−18% | $178.7M+24% | $223.5M+25% | $84.1M−53% | $250.1M+24% | $215.9M+21% | $139.9M−37% | $221.5M+163% | $292M+17% | $129.8M−40% | |
| Net income | $968.8M+18% | $1.1B+57% | −$3.6B | $1B+1% | $913M−6% | $646.3M−41% | $1B | $1.1B+4% | $1.2B+31% | $1B+60% | $1.1B+7% | $653.6M−40% |
| $3.71+18% | $4.21+57% | −$13.92 | $4.01+1% | $3.50−6% | $2.49−41% | $3.99 | $4.20+5% | $4.65+33% | $4.02+61% | $4.31+8% | $2.56−39% | |
| 260.9M+0% | 261.1M+0% | 258.1M−1% | 261M+0% | 260.5M−0% | 259.5M−1% | 258.9M+0% | 257.6M−1% | 256.1M−2% | 256.3M−1% | 255.2M−1% | 255.2M−1% |
Gross profit: 63 periods, Q2 FY10 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY14 and Q4 FY15: quarter's net income to common over its shares, to the cent. 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: Q4 FY14 and Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $3.5B | $3.5B to $3.6B | $4.73 | $4.12 to $5.32 | 11 |
| Q1 FY27 | $3.4B | $3.3B to $3.5B | $4.77 | $4.67 to $4.92 | 4 |
| Q2 FY27 | $3.6B | $3.5B to $3.7B | $5.08 | $4.98 to $5.25 | 4 |
| Q3 FY27 | $3.7B | $3.7B to $3.8B | $5.31 | $5.21 to $5.49 | 7 |
| Q4 FY27 | $3.9B | $3.8B to $4B | $5.67 | $5.55 to $5.85 | 4 |
| Q1 FY28 | $3.5B | $3.4B to $3.6B | $0.00 | 5 | |
| Q2 FY28 | $3.6B | $3.5B to $3.7B | $0.00 | 6 | |
| Q3 FY28 | $3.6B | $3.6B to $3.7B | $0.00 | 9 |
Peers
Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals | $137.1B | 31.5× | 28.6× | 27.9× | 10.9× | +10% | 35.0% |
| REGNRegeneron Pharmaceuticals | $100B | 24.0× | 19.7× | 15.1× | 6.4× | +9% | 27.9% |
| ONCBeOne Medicines | $40.2B | 63.2× | 67.6× | 45.0× | 6.6× | +34% | 10.7% |
| UTHRUnited Therapeutics | $25.9B | 21.6× | 14.2× | 22.6× | 8.2× | +2% | 41.6% |
| INCYIncyte | $24.3B | 15.3× | 36.5× | 51.3× | 4.2× | +27% | 27.7% |
| ALNYAlnylam Pharmaceuticals | $21.2B | 26.7× | 68.2× | 18.9× | 4.4× | +95% | 16.8% |
| EXELExelixis | $17.4B | 22.1× | 22.7× | n/m | 7.1× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | n/m | 4.4× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | n/m | 8.8× | +41% | 24.9% |
| Peer median | $22.8B | 23.0× | 29.6× | 22.6× | 6.5× | +31% | 26.3% |
Investors who own it
Investors we follow who held Vertex Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.1% of portfolioadded
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Vertex Pharmaceuticals
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 29Biotech stocks with the highest profit margins
- #10of 16Biotech stocks with the lowest PE ratio
- #9of 14Biotech stocks with the fastest earnings growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .